MedPath

Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant

Completed
Conditions
Kidney Transplantation
Interventions
Registration Number
NCT01386359
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment, occur in patients taking Nulojix (belatacept) in a real-world setting.

Detailed Description

Time Perspective: Prospective for the majority of patients who are enrolled at the time they begin Nulojix (belatacept) treatment. Retrospective for any patients receiving Nulojix (belatacept) prior to enrollment into ENLiST Registry

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
914
Inclusion Criteria
  • Adult kidney transplant recipient (age ≥18 years at time of transplant)

  • Kidney-only transplant recipient

  • Positive EBV serostatus

    a) EBV serostatus negative or unknown included per the investigator discretion

  • Received first dose of Nulojix (Belatacept) within ≤ 14 days of renal transplant

  • Received first dose of Nulojix (Belatacept) as part of normal clinical care (i.e. not as part of a clinical trial)

Read More
Exclusion Criteria
  • Received Nulojix (belatacept) for non kidney transplants
  • <18 years of age at time of transplant
  • Received first dose of Nulojix (belatacept) as an assigned study drug under a clinical trial protocol
  • EBV-serostatus negative or unknown patients, except by investigator decision
  • Patient who did not receive Belatacept for de novo treatment
  • Recipient of concurrent or extant non-kidney organ transplant
  • Received first dose of Nulojix (belatacept) > 14 days after date of renal transplant
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Adult de novo EBV-seropositive kidney-transplant recipientsNo InterventionAdult de novo EBV-seropositive kidney-transplant recipients treated with Nulojix (belatacept)
Primary Outcome Measures
NameTimeMethod
Incidence rate of confirmed PTLD in US adult de novo Epstein Barr Virus (EBV)-seropositive kidney transplant recipients treated with Nulojix (belatacept) in clinical practiceEvery 6 months for up to 72 months
Incidence rate of confirmed CNS PTLD in US adult de novo Epstein Barr Virus (EBV)-seropositive kidney transplant recipients treated with Nulojix (belatacept) in clinical practiceEvery 6 months for up to 72 months
Incidence rate of PML in confirmed PML in US adult de novo Epstein Barr Virus (EBV)-seropositive kidney transplant recipients treated with Nulojix (belatacept) in clinical practiceEvery 6 months for up to 72 months
Secondary Outcome Measures
NameTimeMethod
Demographic, clinical and treatment characteristics of patients receiving Nulojix (belatacept)Every 6 months for up to 72 months
Rates of graft survival observed in the Nulojix (belatacept) treated patientsEvery 6 months for up to 72 months
Rates of patient survival observed in the Nulojix (belatacept) treated patientsEvery 6 months for up to 72 months
Incidence rate of confirmed PTLD and confirmed CNS PTLD by baseline CMV serostatus among Nulojix (belatacept) treated populationEvery 6 months for up to 72 months
Incidence rates of total reported PTLD, reported CNS PTLD and reported PML in adult de novo EBV seropositive kidney transplant recipients treated with Nulojix (belatacept)Every 6 months for up to 72 months
Incidence rates of total reported PTLD and of total reported CNS PTLD by baseline CMV serostatus among Nulojix (belatacept) treated patientsEvery 6 months for up to 72 months

Trial Locations

Locations (36)

University of Arizona

🇺🇸

Tucson, Arizona, United States

Baystate Medical Center

🇺🇸

Springfield, Massachusetts, United States

Barnes-Jewish Hospital

🇺🇸

Saint Louis, Missouri, United States

Carolinas Medical Center

🇺🇸

Charlotte, North Carolina, United States

Penn State Milton S. Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Univ of Virginia HSC

🇺🇸

Charlottesville, Virginia, United States

Bms Clinical Research Center

🇺🇸

Does Not Exist, New Jersey, United States

Icahn School of Medicine at Mount Sinai

🇺🇸

New York, New York, United States

Lutheran Kidney Transplant Center

🇺🇸

Fort Wayne, Indiana, United States

Maine Medical Center

🇺🇸

Portland, Maine, United States

New York- Presbyterian/ Weill Cornell Medical Canter

🇺🇸

New York, New York, United States

Columbia University Medical Center

🇺🇸

New York, New York, United States

USC University Hospital

🇺🇸

Los Angeles, California, United States

Cedars-Sinai Med Center

🇺🇸

Los Angeles, California, United States

St. Vincent Medical Center - Los Angeles

🇺🇸

Los Angeles, California, United States

California Institute of Renal Research

🇺🇸

San Diego, California, United States

University of California San Francisco Medical Center

🇺🇸

San Francisco, California, United States

University of Colorado School of Medicine

🇺🇸

Aurora, Colorado, United States

Denver Nephrologists

🇺🇸

Denver, Colorado, United States

Yale University (Yale New Haven Hospital)

🇺🇸

New Haven, Connecticut, United States

Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Emory Healthcare - Emory University Hospital (EUH)

🇺🇸

Atlanta, Georgia, United States

Northwestern Memorial Hospital

🇺🇸

Chicago, Illinois, United States

University of Illinois Mecial Center

🇺🇸

Chicago, Illinois, United States

University of Chicago Medical Center

🇺🇸

Chicago, Illinois, United States

The Iowa Clinic

🇺🇸

Des Moines, Iowa, United States

University of Maryland Medical Center

🇺🇸

Baltimore, Maryland, United States

St. Clair Nephrology Research

🇺🇸

Detroit, Michigan, United States

University of Minnesota Medical Center

🇺🇸

Minneapolis, Minnesota, United States

The Christ Hospital Cancer Research

🇺🇸

Cincinnati, Ohio, United States

Integris Baptist Medical Center

🇺🇸

Oklahoma City, Oklahoma, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

UT Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

Swedish Medical Center

🇺🇸

Seattle, Washington, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

University of California, Los Angeles

🇺🇸

Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath